Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biothera has started dosing in an open-label, randomized Phase III trial investigating Imprime PGG in conjunction with cetuximab (Erbitux) to treat recurrent or progressive KRAS wild-type colorectal cancer.
Subscribe to our email newsletter
Imprime PGG is a novel immunomodulatory drug in development as a cancer therapy.
The company expects to recruit around 795 patients in over 50 locations worldwide, including the US, Europe and South America.
The primary endpoint for the study is overall survival.
Secondary endpoints are progression-free survival, tumor response and quality of life.
Biothera Pharmaceutical Group president Dan Conners said based on previous trials, they are confident that the combination of Imprime PGG and cetuximab will prove effective in treating this disease and further extending the survival and quality of life in these patients.